PharmaShots | Incisive News in 3 Shots

Subscribe Now

Symptomatic COVID-19

AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

June 15, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us